Concomitancy and Indications for Idelalisib Use

Details

Basic Details

Date Posted

Monday, March 12, 2018

Status

Complete

Medical Product

bendamustine

bortezomib

chlorambucil

cyclophosphamide

doxorubicin

ibritumomab

ibrutinib

idelalisib

lenalidomide

obinutuzumab

ofatumumab

prednisone

rituximab

vincristine

Description

This report contains estimated numbers of idelalisib users and idelalisib users with concomitant use of several anti-cancer agents as well as cancer diagnoses around the time of idelalisib use. Data from July 23, 2014 to December 31, 2015 from 15 health plans contributing to the Sentinel Distributed Database (SDD) were included in this report. This request was distributed on May 19, 2016.

Deliverables (1)

Sentinel Modular Program Report: Concomitancy and Indications for Idelalisib Use

Additional Information

Additional Details

FDA Center

CDER

Time Period

July 23, 2014 - December 31, 2015

Analysis Type

Descriptive

Population / Cohort

Individuals 18 years of age and older

Data Sources

Sentinel Distributed Database (SDD)